Completed NA INTERVENTIONAL 2-arm NCT01082796

Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects

Investigate the Relationship Between CYP2C19 Genetic Polymorphisms and Pharmacokinetics of Glipizide in Healthy Chinese Subjects

Sponsor: Chinese Academy of Sciences

Conditions Genotype Pharmacokinetic

Interventions Glipizide

Updated 5 times since 2017 Last updated: Mar 8, 2010 Started: Nov 30, 2009 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Genotype and Pharmacokinetic and is currently completed. Chinese Academy of Sciences leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Sciences
LanZhou University

Data source: Chinese Academy of Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lanzhou, China